Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLCAR.CD30 in Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma
NCT04083495Phase 2Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Sep 2019
- Primary completion
- Feb 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ATLCAR.CD30 T cells in peripheral T-cell lymphoma (PTCL), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Sep 2019; status: recruiting.
02
Drugs
ATLCAR.CD30 T cells
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04083495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083495.